Acute Pain Market Forecast Signals Accelerated Growth at a CAGR of 12% During the Forecast Period (2026-2036), Driven by Novel Non-Opioid Therapies and Expanding Treatment Options | DelveInsight

This is less a broad sector catalyst than a dispersion event for names with real regulatory optionality and hospital workflow fit. In acute pain, the bottleneck is not awareness; it is formulary access, anesthesia protocol change, and whether a product reduces total cost of care versus cheap incumbents. That makes VRTX the cleaner equity story if suzetrigine can translate mechanism novelty into repeat institutional use, while VTRS is more of a pricing-and-placement story than a volume explosion.

The biggest loser is likely the incumbent convenience layer: products that sit between the OR and discharge but do not clearly lower opioid rescue use, nursing burden, or length of stay. That puts structural pressure on HRTX and similar hospital-administered analgesics if newer options are simpler to deploy. Second-order, a shift toward opioid-sparing regimens benefits hospital systems and anesthesia groups more than retail channels, because purchasing decisions move upstream into P&T committees and perioperative pathways.

The contrarian point is that the market-size rhetoric probably overstates equity upside: acute pain is a large epidemiology pool but a narrow monetization pool. The real catalyst path is 1-3 months of formulary checks and launch pacing, with 6-18 months of protocol penetration determining whether this becomes a durable franchise or another niche product. Falsifiers are restrictive label language, slow hospital adoption, or a launch that shows low repeat ordering despite favorable awareness.